Long-acting β2-agonists in chronic obstructive pulmonary disease

2002 ◽  
Vol 63 (1) ◽  
pp. 20-23
Author(s):  
Carol Llewellyn-Jones
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Long Acting ◽  
Β2 Agonists

Possibilities of cardiovascular events in patients with chronic obstructive pulmonary disease and newly diagnosed tuberculosis, including those associated with HIV infection, when prescribing long-acting β2-agonists

MedAlliance ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 32-39
Keyword(s):  
Blood Pressure ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Bronchial Obstruction ◽  
External Respiration ◽  
Obstructive Pulmonary Disease ◽  
Tb Treatment ◽  
Long Acting ◽  
Β2 Agonists

Chronic obstructive pulmonary disease (COPD) and pulmonary tuberculosis (TB) are a common pathology among respiratory diseases. Both conditions may have common risk factors, aggravating each other, accom-panied by the development of bronchial obstructive syndrome, requiring mandatory medical correction to increase the effectiveness of therapy for both the main and concomitant pathologies. The aim of the study was to study the effectiveness of treatment of TB in patients with COPD first diagnosed with tuberculosis, including those associated with HIV when prescribing long-acting β2-agonists. Materials and methods. A simple com-parative study included 60 patients of a TB dispensary aged 30–65 years. Patients were divided into 2 groups of 30 people (TB+COPD and TB+COPD+HIV), each of whom for 2 months received a long-acting β-agonist (indacaterol) as an accompanying therapy for the cor-rection of bronchial obstructive syndrome (BOS), with subsequent assessment of the effectiveness of therapy. Results. Subjectively, patients of both groups noted the rapid development of positive dynamics (short-ness of breath decreased from 1–3 days of taking the drug, coughing — within a week, tolerance to physical exertion improved), which was confirmed by indica-tors of the function of external respiration (FEV1). The state of the cardiovascular system was assessed by the results of daily monitoring of blood pressure (BPM). In the COPD+TB group, there is a certain average daily systolic blood pressure (SBP) with a tendency to nor-malize indicators, which is possibly associated with a decrease in the severity of hypoxia during bronchodi-lator therapy. In the COPD+TB+HIV group, the average daily level of SBP increased by 1 mm Hg, but given the very low starting rates, the increase in blood pressure had a positive effect on the patients' condition. The average heart rate (HR) during bronchodilator thera-py did not tend to increase. The best TB treatment re-sults were obtained in the TB+COPD group. In terms of the closure rate of TB+COPD decay cavities — 26.6%, TB+COPD+HIV — 20.0%), the TB+COPD+HIV group had longer periods of abacillation and closure of decay cav-ities, which is associa ted with the severity of the under-lying and associated diseases. The drug was well toler-ated in both groups. Conclusion. The use of 300 mcg long-acting β-adrenomimetics in the complex therapy of β2-adrenergic agonists for patients with TB+COPD and TB+ COPD+HIV can reduce the severity of bronchial obstruction syndrome, improve quality of life, increase adherence to TB treatment, thereby shortening hospi-talization and reduce the likelihood of disability of pa-tients, without the development of side effects from other organs and systems.

scholarly journals [Acute exacerbations in Chronic Obstructive Pulmonary Disease (COPD)]

2017 ◽  
Vol 11 (2) ◽  
Author(s):  
Domenico Lorenzo Urso
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Bacterial Infections ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Systemic Corticosteroids ◽  
Acute Exacerbations ◽  
History Of ◽  
Long Acting ◽  
Β2 Agonists

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. Acute exacerbations of COPD (AECOPD) are important events in the natural history of this condition because they negatively impact health status, rate of hospitalization, disease progression, and mortality.Viral and/or bacterial infections are the main cause of exacerbations. The treatments include systemic corticosteroids, bronchodilators, anticholinergics and/or short- or long-acting β2-agonists, and antibiotics in case of bacterial infections. In some cases, oxygen-therapy is indicated.This article focuses on several aspects of AECOPD, including epidemiology, diagnostic approach, i.e. investigations and management of AECOPD.

The use of inhaled combined therapy in the treatment of asthma and chronic obstructive pulmonary disease

2020 ◽  
Vol 13 (3) ◽  
pp. 358-365
Author(s):  
Katarzyna Górska ◽  
Piotr Korczyński
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Combined Therapy ◽  
Scientific Evidence ◽  
Chronic Obstructive ◽  
Clinical Activity ◽  
Obstructive Pulmonary Disease ◽  
Study Results ◽  
Long Acting ◽  
Β2 Agonists

Clinical study results showed that combined therapy – inhaled glucocorticosteroid plus long-acting β2-agonists – allows for better control of asthma and chronic obstructive pulmonary disease, reducing the number of exacerbations. There are strong scientific evidence for the use of both drugs in one inhaler, because they exhibit complementary and synergy of clinical activity at the molecular level.

Sign in / Sign up

Export Citation Format

Share Document